Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). Also called lupus, SLE is an autoimmune disease. With lupus, the body's immune system targets its own body tissues. Lupus nephritis happens when lupus involves the kidneys. Immune System Related Kidney Disease, funded under NIH clinical trial number NCT00001979, studies patients with autoimmune diseases of the kidney, including lupus nephritis.
lupus transplant population showed no differences in graft or patient survival compared with control subjects. Those patients who received a transplant from 2000 had better results, which may be related to several factors, such as immunosuppression, correction of cardiovascular conditions, or other factors. Risk factors for death and graft loss were similar to the control population. In addition to an ACE inhibitor or an ARB, a diuretic—a medication that helps the kidneys remove fluid from the body.
People with lupus nephritis that is causing high blood pressure may need to take medications that lower their blood pressure and can also significantly slow the progression of kidney disease. Two types of blood pressure lowering medications, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), have proven effective in slowing the progression of kidney disease. Many people require two or more medications to control their blood pressure.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors several programs aimed at better understanding all types of kidney disease, including lupus nephritis. Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis, funded under NIH clinical trial number NCT00774852, compares the addition of the experimental medication abatacept to standard cyclophosphamide therapy with cyclophosphamide therapy alone for treatment of lupus nephritis.